Under the Paperwork Reduction Act of 1995, no persons are req

STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

 Application Number
 10519598

 Filing Date
 2005-09-23

 First Named Inventor
 Cultuso

 At Unit
 1514

 Examinor Name
 Stutry Gentech

 Altomory Docket
 Number

 1765-1332

Remove U.S.PATENTS Pages.Columns.Lines where Name of Patentee or Applicant Examiner Cite Code<sup>1</sup> Issue Date Patent Number Relevant Passages or Relevant Initial\* of cited Document No Figures Appear 1 6245812 2001-03-12 Gollobin 2 5359128 1994-10-25 Blank 5116615 1992-05-26 Gokoen et al. 4 6096764 2000-08-01 Bryant et al. 5 6261800 2001-07-17 Nikolics et al. 6376461 2002-04-23 loari et al. 6353006 2002-03-05 Dixon et al. 6310098 R1 2001-10-30 Guttuso, Jr. Add If you wish to add additional U.S. Patent citation information please click the Add button.

#### 

			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor	n. Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	74
	1									
If you wis	h to ac	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Examiner Cite (cite name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/of country where published.				T5					
1 Gutuso, Neurology 54:2161-2163 (2000)										
2 Thurlow et al., Eur. J. Pharmacol. 247:345-(1995)										
	3 Bryans et al., Med. Res. Rev. 19:149-177 (1999)									
	4	Bryans et al., J. Med. Ch	em. 41:1	838-184	5 (1998)	1				

#### 

	EXAMINER SIGNATURE						
Examiner Signature		Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

See Kint Codes of USPTO Patent Documents at sever USPTO GOV; or MPEP 901.04. Enter of tice that issued the document, by the two-lets of WIPO Standard S13.) For Explaneses patent documents, the includes on the year of the inspect or patent document, provided the patent document.

\*\*Incl of document by the appropriate symbols as indicated on the document under WIPO Standard S11.6 if possible. \*\*Applicant is to place a check mark here if English languages translation is stated.\*\*

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10519598	
Filing Date		2005-09-23	
First Named Inventor	Guttuso		
Art Unit		1614	
Examiner Name	Shirle	ley Gembeh	
Attorney Docket Number		176/61332	

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate select	ion(s):
---------------	----------	------------------	------------------------	---------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ....

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Edwin V. Merkel/	Date (YYYY-MM-DD)	2007-02-05
Name/Print	Edwin V Merkel	Registration Number	40087

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested requested to the process and the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.